4,383 results match your criteria Tardive Dyskinesia


Valbenazine in the treatment of tardive dyskinesia.

Neurodegener Dis Manag 2019 Feb 6. Epub 2019 Feb 6.

Rush University Medical Center, Section of Movement Disorders, Rush Parkinson's Disease & Movement Disorders Program, 1725 W Harrison St., Suite 755, Chicago, IL 60612, USA.

Tardive dyskinesia (TD) is a bothersome and - at times, disabling - movement disorder associated with exposure to dopamine receptor antagonist medications. On 11 April 2017, valbenazine became the first US FDA-approved medication indicated for the treatment of TD. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases the abnormal movements of TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2019-0001DOI Listing
February 2019
1 Read

Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.

Curr Opin Psychiatry 2019 Jan 31. Epub 2019 Jan 31.

Department of Psychiatry, Psychotherapy, and Psychosomatics, Division of Psychiatry I, Medical University Innsbruck, Innsbruck, Austria.

Purpose Of Review: To provide an update on the frequency of antipsychotic-induced tardive dyskinesia and its management in patients with schizophrenia spectrum disorders in studies published since the last systematic review in 2008.

Recent Findings: Recent data about antipsychotic-induced tardive dyskinesia in patients with schizophrenia underscore the superiority of newer generation antipsychotics (21%) over first-generation antipsychotics (30%) with respect to prevalence and incidence rates. Regarding recently tested management strategies, the new vesicular monoamine transporter 2 inhibitors valbenazine and deutetrabenazine have been found to be effective and may be considered as first-line pharmacotherapy for tardive dyskinesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/YCO.0000000000000491DOI Listing
January 2019
1 Read

Deutetrabenazine in the treatment of tardive dyskinesia.

Neurodegener Dis Manag 2019 Jan 31. Epub 2019 Jan 31.

Parkinson's Disease Center & Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, 77030, USA.

Tardive dyskinesia is a common movement disorder in the population of patients taking dopamine receptor blocking agents, such as antipsychotics and certain antiemetics, which likely lead to D2-receptor upregulation and hypersensitization. Efficacious and well-tolerated treatments are now available to reduce symptoms. Deutetrabenazine, a reversible inhibitor of vesicular monoamine transporter 2, was US FDA-approved for treatment of tardive dyskinesia in 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0042DOI Listing
January 2019
1 Read

Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.

J Clin Psychiatry 2018 Dec 18;80(1). Epub 2018 Dec 18.

Neurocrine Biosciences, Inc, San Diego, California, USA.

Background: In the KINECT 3 (NCT02274558; October 2014 to September 2015) study, valbenazine efficacy in tardive dyskinesia (TD) was demonstrated based on mean changes from baseline in the Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1-7). Data from this study were analyzed further to provide a more clinically meaningful interpretation of the primary AIMS results.

Methods: The study included adults who had a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or any mood disorder and also met DSM-IV criteria for neuroleptic-induced TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.18m12278DOI Listing
December 2018
1 Read

Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.

J Clin Psychiatry 2019 Jan 8;80(1). Epub 2019 Jan 8.

FondaMental Foundation, Créteil, France.

Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing.

Objective: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia. Read More

View Article

Download full-text PDF

Source
https://www.psychiatrist.com/JCP/article/Pages/2019/v80/18m1
Publisher Site
http://dx.doi.org/10.4088/JCP.18m12246DOI Listing
January 2019
8 Reads

Trigeminal Meningioma in a Patient with Tardive Dyskinesia as Only Symptom.

Case Rep Neurol Med 2018 31;2018:6175165. Epub 2018 Dec 31.

Clinical County Emergency Hospital of Sibiu, Department of Neurology, Romania.

Most meningiomas are benign, encapsulated tumors (95% of the cases), generally undergoing a limited number of genetic aberrations. We present the case of a 74-year-old patient with no significant pathological history, who is admitted to the neurology ward for orofacial dyskinesias accompanied by hypoesthesia in the left hemiface, a symptomatology that had started insidiously about two months before and worsened progressively over the past 3 weeks. A cerebral MRI was performed which revealed a small mass with discrete T2 hyperintensity and T1 iso-signal compared to the gray matter located in the left pontine cistern, with a large, well-defined base at the level of the cerebral tentorium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6175165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332992PMC
December 2018

Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates.

Mov Disord 2019 Jan 24. Epub 2019 Jan 24.

Faculté de Pharmacie, Université de Montréal, Montréal, Quebec, Canada.

Background: Tardive dyskinesia is a delayed and potentially irreversible motor complication arising from chronic exposure to antipsychotic drugs. Interaction of antipsychotic drugs with G protein-coupled receptors triggers multiple intracellular events. Nevertheless, signaling pathways that might be associated with chronic unwanted effects of antipsychotic drugs remain elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27630DOI Listing
January 2019

Antipsychotics for patients with pain.

Korean J Pain 2019 Jan 2;32(1):3-11. Epub 2019 Jan 2.

Department of Anesthesia and Pain Medicine, Pusan National University, Busan, Korea.

Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain can be summarized as an unpleasant experience, composed of sensory experience caused by actual tissue damage and/or emotional experience caused by potential tissue damage. Less used than antidepressants, antipsychotics have also been used for treating this unpleasant experience as adjuvant analgesics without sufficient evidence from research. Because recently developed atypical antipsychotics reduce the adverse reactions of extrapyramidal symptoms, such as acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia caused by typical antipsychotics, they are expected to be used more frequently in various painful conditions, while increasing the risk of metabolic syndromes (weight gain, diabetes, and dyslipidemia). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3344/kjp.2019.32.1.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333575PMC
January 2019
2 Reads

Potential Application of Yokukansan as a Remedy for Parkinson's Disease.

Evid Based Complement Alternat Med 2018 20;2018:1875928. Epub 2018 Dec 20.

College of Veterinary Medicine and BK21 Plus Project Team, Chonnam National University, Gwangju 61186, Republic of Korea.

Parkinson's disease (PD), the second most common progressive neurodegenerative disorder, is characterized by complex motor and nonmotor symptoms. The clinical diagnosis of PD is defined by bradykinesia and other cardinal motor features, although several nonmotor symptoms are also related to disability, an impaired quality of life, and shortened life expectancy. Levodopa, which is used as a standard pharmacotherapy for PD, has limitations including a short half-life, fluctuations in efficacy, and dyskinesias with long-term use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1875928DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317124PMC
December 2018
3 Reads

A Study on Drug-Induced Tardive Dyskinesia: Orofacial Musculature Involvement and Patient's Awareness.

J Orofac Sci 2018 Jul-Dec;10(2):86-95. Epub 2019 Jan 2.

Department of Oral and Maxillofacial Pathology, Ragas Dental College and Hospital, Affiliated to the Tamil Nadu Dr. M.G.R. Medical University.

Objective: Schizophrenia is a psychiatric disorder that requires long-term treatment. Long-term antipsychotic treatment is often associated with the emergence of tardive dyskinesia (TD), the severity of which is measured by Abnormal Involuntary Movement Scale (AIMS). This study examined the relationship among TD, orofacial musculature activity, and patient's awareness of AIM. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333421PMC
January 2019
4 Reads

The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.

Curr Med Res Opin 2019 Jan 13:1-10. Epub 2019 Jan 13.

b Teva Pharmaceutical Industries , Malvern , PA , USA.

Objective: To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications.

Methods: Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder or bipolar disorder were extracted from a Medicaid claims database. Separate cohorts of TD patients with and without other EPS ("TD + EPS" and "TD non-EPS") were constructed and matched to patients in a non-TD/EPS control cohort at a ∼1:5 ratio. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2019.1569871DOI Listing
January 2019
1 Read

Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors.

World J Biol Psychiatry 2019 Jan 9:1-6. Epub 2019 Jan 9.

f Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology & -Economics , University of Groningen , Groningen , the Netherlands.

Objectives: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD). The authors tried to verify this hypothesis by testing for possible associations between two muscarinic receptor genes (CHRM1 and CHRM2) polymorphisms and TD in patients with schizophrenia.

Methods: A total of 472 patients with schizophrenia were recruited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15622975.2018.1548780DOI Listing
January 2019

No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia.

Hum Psychopharmacol 2019 Jan 8;34(1):e2685. Epub 2019 Jan 8.

Tomsk National Research Medical Center of the Russian Academy of Sciences, Mental Health Research Institute, Tomsk, Russia.

Objective: AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic-induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic-treated patients with schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hup.2685DOI Listing
January 2019
1 Read

Giant Tongue in a Patient With Chiari Malformation and Neuroleptic-Induced Tardive Dyskinesia.

J Craniofac Surg 2018 Dec 29. Epub 2018 Dec 29.

Department of Plastic, Reconstructive and Maxillo-Facial Surgery, and Burn Unit, Centro Hospitalar de São João, Porto Medical School, Alameda Professor Hernâni Monteiro, Porto, Portugal.

A 68-year-old woman, presented with a squamous cell carcinoma of the malar region, and underwent wide local excision. During her clinical examination, repetitive protrusion and intrusion of the tongue as well as stereotypic, abnormal movements of the mouth and lips were observed, in a pattern that resembled chewing, sucking or lip pursing; dyskinesias ceased when she was speaking or bringing food to the mouth. She was unaware of the movements and the tongue was observed to move similar to choreiform movements, while revealing a giant "snake-like" macroglossia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SCS.0000000000005066DOI Listing
December 2018

Current treatment of tardive dyskinesia.

Parkinsonism Relat Disord 2018 Dec 19. Epub 2018 Dec 19.

Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, S-3, Cleveland, OH, 44195, USA. Electronic address:

Tardive dyskinesia (TD) is a common, iatrogenic movement disorder affecting many individuals treated with dopamine-receptor blocking agents (DRBAs). Studying treatment of TD can be complex, as the symptoms can be affected by changes in either dosage or type of DRBA, as well as by the variable natural course of the disease. Historically many pharmacological therapies have been studied in TD, finding varying degrees of treatment success. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183055
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.12.022DOI Listing
December 2018
6 Reads

The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.

J Affect Disord 2019 03 17;246:217-223. Epub 2018 Dec 17.

Neurocrine Biosciences, Inc., San Diego, CA, United States.

Background: Few studies have assessed the treatment of tardive dyskinesia (TD) in patients with primary mood disorders who are managed with antipsychotics. The effects of once-daily valbenazine on TD were evaluated in adults with a bipolar or depressive disorder.

Methods: Data were pooled from two 6-week double-blind placebo-controlled trials (KINECT 2 and KINECT 3; 114 mood participants) and a long-term blinded extension study (KINECT 3 extension; 77 mood participants) of valbenazine in adults with TD. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01650327183128
Publisher Site
http://dx.doi.org/10.1016/j.jad.2018.12.023DOI Listing
March 2019
8 Reads

Risperidone-Induced Tardive Dyskinesia in an Autistic Child.

Authors:
Vasco Kidd

Prim Care Companion CNS Disord 2018 Dec 6;20(6). Epub 2018 Dec 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.18l02283DOI Listing
December 2018
2 Reads

Tardive dyskinesia: Who gets it and why.

Authors:
Karen Frei

Parkinsonism Relat Disord 2018 Nov 15. Epub 2018 Nov 15.

Loma Linda University, Loma Linda, CA, USA. Electronic address:

Tardive dyskinesia (TD) is a potentially permanent movement disorder resulting from chronic use of dopamine receptor blocking agents (DRBA). Identified risk factors include the type of antipsychotic agent, being greater for those of first generation antipsychotics (FGA), the duration of illness and cumulative dose of DRBA and advanced age. Female sex and African and Caucasian ethnicity are additional potential risk factors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183051
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.017DOI Listing
November 2018
8 Reads

[Extrapyramidal adverse reactions to metoclopramide. A pharmacovigilance survey].

Rev Med Chil 2018 Jul;146(7):876-884

Servicio de Farmacia, Hospital La Ligua, La Ligua, Chile.

Background: In 2013 the Chilean regulatory sanitary agency issued a warning concerning dose adjustment and use restriction to avoid severe adverse effects of metoclopramide such tardive dyskinesia.

Aim: To study dyskinesia type adverse effects in a population using metoclopramide.

Material And Methods: A cross sectional observational study was conducted among patients pertaining to palliative care and diabetes mellitus programs and consuming 10 mg/day or more of metoclopramide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/s0034-98872018000700876DOI Listing
July 2018
1 Read

Setting the record straight: The nosology of tardive syndromes.

Parkinsonism Relat Disord 2018 Nov 28. Epub 2018 Nov 28.

Department of Neurology, Loma Linda University Medical Center, Loma Linda, CA, USA.

We propose the use of the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements and the analogous repetitive movements of the limbs, trunk, or pelvis. The term tardive syndrome is an umbrella term to be used to refer to the spectrum of all persistent hyperkinetic, hypokinetic, and sensory phenomenologies resulting from chronic dopamine receptor blocking agent (DRBA) exposure. TD is a type of TS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183052
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.025DOI Listing
November 2018
2 Reads

Quantitative DNA Methylation Analysis of DLGAP2 Gene using Pyrosequencing in Schizophrenia with Tardive Dyskinesia: A Linear Mixed Model Approach.

Sci Rep 2018 Nov 30;8(1):17466. Epub 2018 Nov 30.

Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, 100096, China.

Tardive dyskinesia (TD) is a side effect of antipsychotic medications used to treat schizophrenia (SCZ) and other mental health disorders. No study has previously used pyrosequencing to quantify DNA methylation levels of the DLGAP2 gene; while the quantitative methylation levels among CpG sites within a gene may be correlated. To deal with the correlated measures among three CpG sites within the DLGAP2 gene, this study analyzed DNA methylation levels of the DLGAP2 gene using a linear mixed model (LMM) in a Chinese sample consisting of 35 SCZ patients with TD, 35 SCZ without TD (NTD) and 34 healthy controls (HCs) collected in Beijing, China. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-35718-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269460PMC
November 2018
1 Read

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma.

Cureus 2018 Sep 24;10(9):e3349. Epub 2018 Sep 24.

Hematology and Oncology, University of Arizona, Tucson, USA.

Lenalidomide is commonly used as induction or maintenance therapy in multiple myeloma. We report a case of 71-year-old female presenting with tardive dyskinesia-like symptoms one month after starting her lenalidomide maintenance therapy after high-dose chemotherapy and autologous hematopoietic stem cell rescue. Her symptoms evolved over days to pronounced uncontrollable limb movements, tongue smacking, lip-smacking, abnormal sounds, and tongue biting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255714PMC
September 2018
1 Read

Tardive Oculogyric Crisis With Low-Dose Antipsychotic in an Adolescent: A Case Report.

Authors:
Sundar Gnanavel

Prim Care Companion CNS Disord 2018 Nov 22;20(6). Epub 2018 Nov 22.

View Article

Download full-text PDF

Source
http://www.psychiatrist.com/PCC/article/Pages/2018/v20n06/18
Publisher Site
http://dx.doi.org/10.4088/PCC.18l02275DOI Listing
November 2018
11 Reads

A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.

Agri 2018 Oct;30(4):199-201

Department of Anesthesiology and Reanimation, Zile State Hospital, Tokat, Turkey.

Tardive dyskinesia and tardive dystonia are caused by dopamine receptor blocking agents, mostly antipsychotics and sometimes antidepressants or calcium channel blockers. Duloxetine is a serotonin-noradrenaline reuptake inhibitor used in the treatment of diabetic neuropathic pain and fibromyalgia, as well as major depression. In this case, we aimed to discuss the tardive dyskinesia-like appearance of a patient using duloxetine due to fibromyalgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5505/agri.2018.60134DOI Listing
October 2018
18 Reads

Using an Integrated Care Pathway for Late-Life Schizophrenia Improves Monitoring of Adverse Effects of Antipsychotics and Reduces Antipsychotic Polypharmacy.

Am J Geriatr Psychiatry 2019 Jan 14;27(1):84-90. Epub 2018 Sep 14.

Adult Neurodevelopment and Geriatric Psychiatry Division (PSA, TS, KP, BHM, TKR), Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry (PSA, TS, KP, BHM, TKR), University of Toronto, Toronto, Ontario, Canada.

Objective: Antipsychotic use in older patients is associated with many adverse effects, including tardive dyskinesia and extrapyramidal symptoms, which, in turn, increase the risk of falling. Antipsychotics are also associated with metabolic syndrome and cognitive impairment in older patients. Integrated care pathways (ICPs) are designed to manage specific conditions using standardized assessments and measurement-based interventions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10647481183048
Publisher Site
http://dx.doi.org/10.1016/j.jagp.2018.09.003DOI Listing
January 2019
19 Reads

Tardive Dyskinesia Should Not Be Overlooked.

J Child Adolesc Psychopharmacol 2019 Feb 2;29(1):72-74. Epub 2018 Nov 2.

1 Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/cap.2018.0084
Publisher Site
http://dx.doi.org/10.1089/cap.2018.0084DOI Listing
February 2019
9 Reads

Changes in recruitment of motor cortex excitation and inhibition in patients with drug-induced tardive syndromes.

Neurophysiol Clin 2019 Feb 23;49(1):33-40. Epub 2018 Oct 23.

Sobell Department of Motor Neuroscience and movement Disorders, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Objectives: It has recently been suggested that drug-induced tardive syndromes (TS) might be due to maladaptive plasticity, which increases motor excitability in cerebral cortex and basal ganglia. In order to test this hypothesis, we performed the first measurements of cortical excitability in TS.

Methods: Motor cortex excitability was examined using transcranial magnetic stimulation (TMS) in 22 TS patients and compared with that in 20 age and sex-matched healthy individuals. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09877053183021
Publisher Site
http://dx.doi.org/10.1016/j.neucli.2018.10.001DOI Listing
February 2019
9 Reads

Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Drugs Aging 2018 11;35(11):959-971

Department of Neurology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9.100 SN, 28034, Madrid, Spain.

Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are iatrogenic consequences of antidopaminergic drugs. Both are particularly prevalent among the elderly and those with dementia. However, despite their prevalence, these disorders are often overlooked. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-018-0590-yDOI Listing
November 2018

[Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Nervenarzt 2018 Oct 19. Epub 2018 Oct 19.

Zentrum für Psychosoziale Medizin, Klinik für Allgemeine Psychiatrie, Universität Heidelberg, Heidelberg, Deutschland.

The treatment of schizophrenic psychoses with antipsychotic drugs (AP) is often associated with an increased risk of delayed occurrence of antipsychotic-associated movement disorders. Persistence and chronicity of such symptoms are very frequent. The risk of developing tardive dyskinesia (TD) is associated with the pharmacological effect profile of a particular AP, with treatment duration and age. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00115-018-0629-7
Publisher Site
http://dx.doi.org/10.1007/s00115-018-0629-7DOI Listing
October 2018
12 Reads

Lithium monotherapy-induced tardive dyskinesia.

J Affect Disord 2019 02 9;244:78-79. Epub 2018 Oct 9.

Laboratory of Clinical Neurophysiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Tardive dyskinesia is a movement disorder that develops during the course of long-term treatment with neuroleptic agents and is characterized primarily by choreiform and athetotic movements. We report the case of a 68-year old female suffering from Bipolar disorder, treated with lithium monotherapy 600 mg per day (serum levels 0.6) for the last 15 years. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01650327183211
Publisher Site
http://dx.doi.org/10.1016/j.jad.2018.10.094DOI Listing
February 2019
10 Reads

Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.

J Neural Transm (Vienna) 2019 Feb 13;126(2):183-191. Epub 2018 Oct 13.

Sobell Department of Motor Neuroscience and Movement Disorders, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Tardive syndromes (TDS) typically manifest 3 months or later after exposure to antipsychotic drugs, and unfortunately have no satisfactory medical treatment. We explored the possibility of using therapeutic repetitive transcranial magnetic stimulation (rTMS). Twenty-six patients were allocated to receive real or sham rTMS over the hand/arm area of motor cortex (M1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-018-1941-xDOI Listing
February 2019
17 Reads

Diabetic gastroparesis: current challenges and future prospects.

Clin Exp Gastroenterol 2018 25;11:347-363. Epub 2018 Sep 25.

Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center, El Paso, TX, USA,

Diabetic gastroparesis (DMGP) is a condition of delayed gastric emptying after gastric outlet obstruction has been excluded. Symptoms of nausea, vomiting, early satiety, bloating, and abdominal pain are associated with DMGP. Uncontrolled symptoms can lead to overall poor quality of life and financial burdens on the healthcare system. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/diabetic-gastroparesis-current-cha
Publisher Site
http://dx.doi.org/10.2147/CEG.S131650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165730PMC
September 2018
4 Reads

VMAT2 Inhibitors in Neuropsychiatric Disorders.

CNS Drugs 2018 Dec;32(12):1131-1144

Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 7200 Cambridge St., 9th floor, Houston, TX, 77030, USA.

The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have recently gained more attention following their development for specific indications in the United States. At present, there are three commercially available VMAT2 inhibitors: tetrabenazine, deutetrabenazine, and valbenazine. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40263-018-0580-y
Publisher Site
http://dx.doi.org/10.1007/s40263-018-0580-yDOI Listing
December 2018
22 Reads

Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis.

Front Pharmacol 2018 18;9:974. Epub 2018 Sep 18.

Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Tardive dyskinesia (TD) is a movement disorder that may occur after extended use of antipsychotic medications. The etiopathophysiology is unclear; however, genetic factors play an important role. The Perlecan () gene was found to be significantly associated with TD in Japanese schizophrenia patients, and this association was subsequently replicated by an independent research group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2018.00974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157325PMC
September 2018
17 Reads

Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.

J Clin Psychiatry 2018 Sep 18;79(6). Epub 2018 Sep 18.

Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.

Objective: Tardive dyskinesia (TD) is an antipsychotic-induced movement disorder that typically occurs after long-term exposure to antipsychotic drugs. There is evidence that switching to clozapine reduces TD. This meta-analysis reviews the effect of switching to clozapine on the severity of TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.17r11852DOI Listing
September 2018
10 Reads

Acute dopamine receptor blockade in substantia nigra pars reticulata: a possible model for drug-induced Parkinsonism.

J Neurophysiol 2018 Dec 26;120(6):2922-2938. Epub 2018 Sep 26.

División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México , México City, México.

Dopamine (DA) depletion modifies the firing pattern of neurons in the substantia nigra pars reticulata (SNr), shifting their mostly tonic firing toward irregularity and bursting, traits of pathological firing underlying rigidity and postural instability in Parkinson's disease (PD) patients and animal models of Parkinsonism (PS). Drug-induced Parkinsonism (DIP) represents 20-40% of clinical cases of PS, becoming a problem for differential diagnosis, and is still not well studied with physiological tools. It may co-occur with tardive dyskinesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/jn.00579.2018DOI Listing
December 2018
1 Read

Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial.

Brain Stimul 2018 Nov - Dec;11(6):1368-1377. Epub 2018 Sep 11.

Department of Neurology and Neurosurgery, Heinrich-Heine-University, Düsseldorf, Germany.

Introduction: Growing evidence suggests that pallidal deep brain stimulation represents a potential new therapeutic avenue in tardive dystonia/dyskinesia, but controlled and blinded randomized studies (RCT) are missing. The present RCT compares dystonia/dyskinesia severity of pallidal neurostimulation in patients with tardive dystonia using a delayed-start design paradigm.

Methods: Dystonia/dyskinesia severity was assessed via blinded videos following pallidal neurostimulation at 3 (blinded phase) and 6 months (open extension phase). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brs.2018.08.006DOI Listing
September 2018
5 Reads

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.

BMC Psychiatry 2018 Sep 24;18(1):306. Epub 2018 Sep 24.

Teva Pharmaceutical Industries, 41 Moores Rd, Frazer, Malvern, PA, 19355, USA.

Background: Data are limited on the benefits and risks of dose reduction in managing side effects associated with antipsychotic treatment. As an example, antipsychotic dose reduction has been recommended in the management of tardive dyskinesia (TD), yet the benefits of lowering doses are not well studied. However, stable maintenance treatment is essential to prevent deterioration and relapse in schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12888-018-1889-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154822PMC
September 2018
1 Read

Uncoupling DISC1 × D2R Protein-Protein Interactions Facilitates Latent Inhibition in Disc1-L100P Animal Model of Schizophrenia and Enhances Synaptic Plasticity via D2 Receptors.

Front Synaptic Neurosci 2018 7;10:31. Epub 2018 Sep 7.

School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, China.

Both Disrupted-In-Schizophrenia-1 (DISC1) and dopamine receptors D2R have significant contributions to the pathogenesis of schizophrenia. Our previous study demonstrated that DISC1 binds to D2R and such protein-protein interaction is enhanced in patients with schizophrenia and Disc1-L100P mouse model of schizophrenia (Su et al., 2014). Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fnsyn.2018.00031
Publisher Site
http://dx.doi.org/10.3389/fnsyn.2018.00031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137395PMC
September 2018
11 Reads

Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.

Brain Behav Immun 2018 Nov 11;74:241-251. Epub 2018 Sep 11.

Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Brazil.

The chronic use of drugs that reduce the dopaminergic neurotransmission can cause a hyperkinetic movement disorder called tardive dyskinesia (TD). The pathophysiology of this disorder is not entirely understood but could involve oxidative and neuroinflammatory mechanisms. Cannabidiol (CBD), the major non-psychotomimetic compound present in Cannabis sativa plant, could be a possible therapeutic alternative for TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbi.2018.09.014DOI Listing
November 2018
3 Reads

Management of common adverse effects of antipsychotic medications.

World Psychiatry 2018 Oct;17(3):341-356

Department of Psychiatry, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.

The benefits of antipsychotic medications are sometimes obscured by their adverse effects. These effects range from relatively minor tolerability issues (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wps.20567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127750PMC
October 2018
2 Reads

Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.

World Psychiatry 2018 Oct;17(3):330-340

Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.

Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial agonists (second-generation antipsychotics, SGAs) is considered significantly lower than with D2 antagonists (first-generation antipsychotics, FGAs). As some reports questioned this notion, we meta-analyzed randomized controlled studies (RCTs) to estimate the risk ratio (RR) and annualized rate ratio (RaR) of TD comparing SGAs vs. FGAs and SGAs vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wps.20579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127753PMC
October 2018
19 Reads

Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.

Tremor Other Hyperkinet Mov (N Y) 2018 31;8:570. Epub 2018 Aug 31.

Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.

Background: Although tardive dyskinesia (TD) is most commonly defined as a movement disorder caused by chronic exposure to dopamine-receptor-blocking drugs (DRBDs), it has also been thought to result from exposure to some non-DRBDs.

Methods: We critiqued many reviews making the association between non-DRBDs and a TD-like syndrome and almost all case reports. We checked whether cases met criteria for the diagnosis of TD-like syndrome and whether DRBDs had been excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/D8FF58Z9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125739PMC
November 2018
1 Read

Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?

Authors:
Stephen M Stahl

CNS Spectr 2018 Aug;23(4):239-247

The two approved treatments for tardive dyskinesia both inhibit the vesicular monoamine transporter type 2 (VMAT2) yet have pharmacologic properties that distinguish one from the other. Knowing these differences may help optimize which treatment to select for individual patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852918001219DOI Listing
August 2018
15 Reads

Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement.

Sci Rep 2018 Aug 27;8(1):12884. Epub 2018 Aug 27.

Peking University HuiLongGuan Clinical Medical School, Beijing, P. R. China.

Tardive dyskinesia (TD) is a devastating motor disorder associated with the etiological process of schizophrenia or antipsychotic medication treatments. To examine whether cerebral morphological changes may manifest in TD, we used voxel-based morphometry to analyze high-resolution T1-weighted brain structural magnetic resonance images from 32 schizophrenics with TD (TD group), 31 schizophrenics without TD (non-TD group), and 32 healthy controls (HC group). We also assessed psychopathological symptoms with the Positive and Negative Syndrome Scale (PANSS), and TD severity with the Abnormal Involuntary Movement Scale (AIMS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-31186-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110787PMC
August 2018
14 Reads

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Nicotine Tob Res 2019 Feb;21(3):357-369

Center for Health Sciences, SRI International, Menlo Park, CA.

Emerging studies indicate that striatal cholinergic interneurons play an important role in synaptic plasticity and motor control under normal physiological conditions, while their disruption may lead to movement disorders. Here we discuss the involvement of the cholinergic system in motor dysfunction, with a focus on the role of the nicotinic cholinergic system in Parkinson's disease and drug-induced dyskinesias. Evidence for a role for the striatal nicotinic cholinergic system stems from studies showing that administration of nicotine or nicotinic receptor drugs protects against nigrostriatal degeneration and decreases L-dopa-induced dyskinesias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ntr/nty063DOI Listing
February 2019
6 Reads

Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals.

Ann Pharmacother 2018 Aug 23:1060028018797110. Epub 2018 Aug 23.

1 University at Buffalo, Buffalo, NY, USA.

Objective: Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018797110DOI Listing
August 2018
12 Reads

Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review.

CNS Drugs 2018 Oct;32(10):917-938

Department of Psychiatry, University of British Columbia, Room A3-111, 938 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.

Background: Although antipsychotics are used to treat Tourette syndrome, there have been reports of paradoxical induction of tics by first- and second-generation antipsychotics.

Objective: The objective of this systematic review was to better characterize tics as the potential adverse effect of antipsychotics.

Methods: A literature search was performed, with no language restriction, using the MEDLINE, EMBASE, and PsycINFO databases for all publications up to January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-018-0559-8DOI Listing
October 2018
7 Reads
5.113 Impact Factor